Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
Mark D. Berry, Raul R. Gainetdinov, Marius C. Hoener, et al.
Pharmacology & Therapeutics (2017) Vol. 180, pp. 161-180
Open Access | Times Cited: 199

Showing 1-25 of 199 citing articles:

Trace Amines and Their Receptors
Raul R. Gainetdinov, Marius C. Hoener, Mark D. Berry
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 549-620
Open Access | Times Cited: 321
Gut Microbial Metabolites of Aromatic Amino Acids as Signals in Host–Microbe Interplay
Yali Liu, Yuanlong Hou, Guangji Wang, et al.
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 11, pp. 818-834
Closed Access | Times Cited: 256
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Simone B. Sartori, Nicolas Singewald
Pharmacology & Therapeutics (2019) Vol. 204, pp. 107402-107402
Open Access | Times Cited: 205
The Case for TAAR1 as a Modulator of Central Nervous System Function
Grazia Rutigliano, Alice Accorroni, Riccardo Zucchi
Frontiers in Pharmacology (2018) Vol. 8
Open Access | Times Cited: 139
Augmentation of Extinction and Inhibitory Learning in Anxiety and Trauma-Related Disorders
Lauren A. M. Lebois, Antonia V. Seligowski, Jonathan D. Wolff, et al.
Annual Review of Clinical Psychology (2019) Vol. 15, Iss. 1, pp. 257-284
Open Access | Times Cited: 81
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
Daniil Grinchii, Eliyahu Dremencov
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9532-9532
Open Access | Times Cited: 79
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
Nina Dedic, Heather Dworak, Courtney Zeni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13185-13185
Open Access | Times Cited: 77
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
Recognition of methamphetamine and other amines by trace amine receptor TAAR1
Heng Liu, You Zheng, Yue Wang, et al.
Nature (2023) Vol. 624, Iss. 7992, pp. 663-671
Closed Access | Times Cited: 34
Ligand recognition and G-protein coupling of trace amine receptor TAAR1
Zheng Xu, Lulu Guo, Jingjing Yu, et al.
Nature (2023) Vol. 624, Iss. 7992, pp. 672-681
Closed Access | Times Cited: 32
Structural and signaling mechanisms of TAAR1 enabled preferential agonist design
Pan Shang, Naikang Rong, Jingjing Jiang, et al.
Cell (2023) Vol. 186, Iss. 24, pp. 5347-5362.e24
Open Access | Times Cited: 27
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23
Molecular basis of human trace amine-associated receptor 1 activation
Gregory Zilberg, Alexandra Kalia Parpounas, Audrey L. Warren, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Trace Amine-Associated Receptor 5 Provides Olfactory Input Into Limbic Brain Areas and Modulates Emotional Behaviors and Serotonin Transmission
Stefano Espinoza, Ilya Sukhanov, Evgeniya V. Efimova, et al.
Frontiers in Molecular Neuroscience (2020) Vol. 13
Open Access | Times Cited: 55
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr, et al.
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 89-108
Open Access | Times Cited: 52
Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?
Seetal Dodd, André F. Carvalho, Basant K. Puri, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 120, pp. 537-541
Closed Access | Times Cited: 51
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2520-2520
Open Access | Times Cited: 33
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Alejandro Díaz‐Holguín, Marcus Saarinen, Duc Duy Vo, et al.
Science Advances (2024) Vol. 10, Iss. 32
Open Access | Times Cited: 7
Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs
Pramod C. Nair, Britto Shajan, Tarun Bastiampillai
Molecular Psychiatry (2024) Vol. 29, Iss. 6, pp. 1925-1928
Closed Access | Times Cited: 6
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1739-1739
Open Access | Times Cited: 6
Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases
Michael D. Schwartz, Juan J. Canales, Riccardo Zucchi, et al.
Expert Opinion on Therapeutic Targets (2018) Vol. 22, Iss. 6, pp. 513-526
Open Access | Times Cited: 55
p ‐Synephrine, ephedrine, p ‐octopamine and m ‐synephrine: Comparative mechanistic, physiological and pharmacological properties
S.J. Stohs, Mohd Shara, Sidhartha D. Ray
Phytotherapy Research (2020) Vol. 34, Iss. 8, pp. 1838-1846
Open Access | Times Cited: 48
TAAR Agonists
Zhengrong Xu, Qian Li
Cellular and Molecular Neurobiology (2019) Vol. 40, Iss. 2, pp. 257-272
Closed Access | Times Cited: 43
Page 1 - Next Page

Scroll to top